Amneal Pharma Shares Rise After FDA Approves Generic Drug for $983M Market

Amneal Pharmaceuticals (NASDAQ: AMRX) has received approval from the U.S. Food and Drug Administration (FDA) for its generic Lanreotide Injection, a development that grants the company access to a significant specialty drug market. The approval, announced on September 18, clears the product for immediate commercial launch.

Strategic Market Entry

The newly approved drug is a generic equivalent to Ipsen's Somatuline Depot, a branded treatment used for certain types of tumors. The market for this drug is substantial; according to a report from Investing.com, the branded version generated approximately $983 million in U.S. sales in the twelve months ending July 2026.

This approval allows Amneal to compete for a share of this lucrative market, representing a key strategic win for the company's generic drug portfolio. The launch builds on positive momentum from the company's second-quarter financial results, which included a revenue beat and raised full-year guidance to around $3.15 billion.

Ad

Stock Performance and Valuation

Investors reacted positively to the news. On September 21, shares of Amneal Pharmaceuticals jumped 7.8% in a single session to close at $20.16. The stock's performance has been strong throughout the year, with a year-to-date gain of approximately 60%.

The recent rally has pushed the stock near the top of its 52-week range of $9.49 to $21.18. Amneal, a mid-cap company, currently has a market capitalization of between $6.5 billion and $7 billion, as noted in the source report.